US Executive Compensation Proxy SEC Filings — October 22, 2026

22-10-2026

Paylocity Holding Corporation filed its definitive DEF 14A proxy statement on October 22, 2026 for its Annual Meeting of Stockholders on December 3, 2026, to be held virtually. Stockholders will vote on electing nine directors, ratifying KPMG LLP as auditor for fiscal 2027, a non-binding say-on-pay advisory vote, and approval of the Second Amended and Restated 2023 Equity Incentive Plan. The filing contains governance and voting information; it does not report financial results, so no period-over-period performance comparison is provided.

• · Annual meeting date: Thursday, December 3, 2026 at 8:30 a.m. Central Time, held virtually at www.virtualshareholdermeeting.com/PCTY2026
• · Record date: close of business October 6, 2026; votes by internet or telephone due by 11:59 p.m. Eastern Time on December 2, 2026
• · Director elections use a plurality standard; broker non-votes and withheld votes have no effect on director elections
• · Abstentions count as votes against the auditor ratification, say-on-pay, and equity plan proposals
• · Board recommends FOR on all four proposals; KPMG LLP proposed as auditor for fiscal year ending June 30, 2027
• · Fiscal 2026 covered July 1, 2025 through June 30, 2026; the filing contains executive compensation tables for named executive officers Toby J. Williams and Steven R. Beauchamp

21-10-2026

PowerCompute, Inc. (filed under LM Funding America, Inc. / LMFA in the request) has filed a DEF 14A definitive proxy statement for a Special Meeting of Stockholders on November 17, 2026, in Tampa, Florida. The sole substantive proposal is a reverse stock split at an exchange ratio between 1-for-2 and 1-for-10, with the exact ratio to be set by the Board, plus an adjournment proposal to solicit additional votes if needed. The Board recommends voting FOR both proposals.

• · Special Meeting date and time: November 17, 2026 at 3:00 pm local time; stockholders admitted from 2:45 pm, at 1200 West Platt Street, Suite 100, Tampa, Florida 33606
• · Record date: October 16, 2026; proxy materials expected to be mailed on or about October 20, 2026
• · Reverse split approval standard: votes cast for must exceed votes cast against; abstentions and broker non-votes have no effect
• · Adjournment Proposal requires a majority of shares present and entitled to vote; an abstention has the same effect as a vote against
• · Company expects no broker non-votes because both proposals are treated as routine matters
• · Reverse split is conditional: the amendment is effective only if the Board deems it advisable, and the exact ratio will be determined by the Board
• · Proxies may be revoked before the meeting by written notice to the Secretary or a later-dated proxy; cameras and recording devices are prohibited at the meeting
• · Filing discrepancy: the registrant named in the filing is PowerCompute, Inc., while the request identifies the filer as LM Funding America, Inc. (LMFA); this should be verified against EDGAR before publication

21-10-2026

Microsoft's DEF 14A proxy statement for fiscal year 2026 (ended June 30, 2026) sets out board governance, committee composition, and the slate for the 2026 Annual Meeting. 11 of 12 director nominees are independent, with CEO Satya Nadella as the sole non-independent nominee; the average independent director tenure is 6.7 years (6.8 years including Nadella). Mr. Hoffman and Mr. Johnston are not seeking re-election, and John Collison is nominated for election to the Board.

• · Board committees include the Audit and Finance, Compensation, Environmental Social and Public Policy, and Governance and Nominating committees, all composed solely of independent directors.
• · Director Teri L. List serves on four public company audit committees, which the Board reviewed and determined does not impair her ability to serve on Microsoft's Audit and Finance Committee.
• · Pay Governance LLC serves as the independent compensation consultant to the Compensation Committee and provides no other services to Microsoft.
• · Independent directors hold executive sessions at each quarterly Board meeting without management present.
• · Board committees will consider appointments for John Collison if elected at the Annual Meeting.

21-10-2026

20/20 Biolabs, Inc. (AIDX) has filed a definitive proxy statement for a virtual Special Meeting of Stockholders on December 9, 2026, seeking stockholder authorization for the board to implement one or more reverse stock splits at ratios between 1-for-2 and 1-for-250 at any time before December 31, 2028. A second proposal seeks authority to adjourn the meeting if insufficient votes are obtained. The filing lists 13,367,204 common shares outstanding as of the October 20, 2026 record date, and the board recommends voting FOR both proposals.

• · Special Meeting date: Wednesday, December 9, 2026 at 10:00 a.m. Eastern Time, held solely via live webcast
• · Notice of Internet Availability of Proxy Materials expected to be mailed on or about October 22, 2026
• · Record Date: October 20, 2026; company states no other business is expected as stockholder proposal deadlines have passed
• · Company headquarters listed as Gaithersburg, MD (mail address) with Rockville, MD business address on EDGAR header
• · Filing fee: no fee required (Schedule 14A)

21-10-2026

Pyxis Oncology, Inc. has filed a definitive proxy statement for a virtual Special Meeting of Stockholders on November 13, 2026, asking shareholders to approve an amendment to its Certificate of Incorporation increasing authorized common stock from 190,000,000 to 380,000,000 shares (a doubling), plus an adjournment proposal. The Board recommends voting FOR both proposals. With 119,583,637 shares outstanding as of the October 8, 2026 record date, the increase would roughly double the authorized share count while leaving substantial headroom above current outstanding shares.

• · Special Meeting set for November 13, 2026 at 10:00 a.m. EST, virtual-only, registration required at www.proxydocs.com/PYXS
• · Abstentions and unvoted shares, including broker non-votes, have the same effect as a vote AGAINST Proposal One, which requires a majority of outstanding shares
• · Brokers are expected to have discretionary authority on both proposals, so broker non-votes are not expected
• · Proxy materials mailed on or about October 21, 2026; the filing was made without a fee

21-10-2026

Personalis, Inc. (Nasdaq: PSNL) has entered into a merger agreement with Tempus under which Personalis will become a wholly owned subsidiary of Tempus through a two-step merger structure, with Personalis' successor entity renamed 'Personalis, LLC.' Stockholders will vote on the Merger Proposal at a virtual special meeting on November 30, 2026, where approval requires a majority of outstanding shares; Merck (approximately 13%) and Tempus (approximately 12%) hold a combined stake that leaves roughly 27.1 million shares from other holders needed to secure approval. The filing does not disclose the per-share consideration amount in the excerpt provided.

• · Each in-the-money Personalis option held by former employees or non-employee directors, or vested and held by current service providers, is cancelled for Stock Consideration net of exercise price; other in-the-money options are assumed and converted into Tempus Class A options; out-of-the-money options are cancelled without consideration.
• · Unvested Personalis PSUs vest on a prorated basis at closing; the remainder convert into time-based Tempus RSUs vesting quarterly over the rest of the performance period.
• · Non-employee director RSUs fully accelerate at the Effective Time and are cashed out.
• · The Personalis Employee Stock Purchase Plan terminates effective immediately before the Effective Time, with any current offering period accelerated to within 10 business days of closing.
• · Post-merger, Personalis will have no board or officers and will be governed as a wholly owned Tempus subsidiary; Tempus has no current plans for extraordinary transactions beyond the Mergers but reserves the right to pursue acquisitions, dispositions, or asset reorganizations.
• · The Merger Compensation Proposal (non-binding advisory vote on golden parachute compensation) and an Adjournment Proposal are also on the November 30, 2026 meeting agenda.
• · Brokers have no discretionary voting authority on any proposal, so no broker non-votes are expected.
• · The Personalis board unanimously determined the merger is fair to and in the best interests of Personalis and its unaffiliated stockholders, and recommends that stockholders adopt the Merger Agreement.
• · Tempus stockholder approval is not required for the Mergers or the share issuance in the First Merger.

22-10-2026

IGC Pharma's DEF 14A combines a CEO letter and a notice of the December 2, 2026 Annual Meeting. The letter reports that CALMA, the Phase 2 trial of IGC-AD1 for Alzheimer's agitation, reached 100% planned enrollment on September 28, 2026, with final dosing expected in November 2026 and no serious treatment-related adverse events identified in blinded monitoring. For the nine months ended December 31, 2025, revenue fell to $869 thousand from $941 thousand, gross profit fell from $465 thousand to $297 thousand, and operating loss widened to $7.7 million from $6.0 million, while net loss narrowed to $4.1 million from $5.9 million only because of non-cash other income of $3.6 million.

• · Operating spending (R&D plus SG&A) rose to about $8.0M from $6.5M, with R&D driving roughly three-quarters of the operating loss increase
• · Gross profit fell 36% on lower revenue, a decline not mentioned in the CEO letter
• · Non-cash other income of $3.6M, including the $1.1M Vancouver gain and $2.1M dissolution gain, masked the operating loss deterioration in the net loss figure
• · Net loss narrowed 30% only because of non-cash gains; cash used in operations rose to $4.7M from $4.1M
• · Cash raised from common stock sales of about $5.2M results in ongoing shareholder dilution
• · Two patents granted (Nov and Dec 2025) and a Canadian Notice of Allowance (Feb 2026) protect IGC-AD1 formulation and composition
• · CALMA safety data remain subject to final review after database lock and unblinding; the letter states safety findings do not indicate efficacy
• · IGC-1C and IGC-M3 remain at early preclinical stage
• · Shareholder vote on Annual Meeting proposals occurs December 2, 2026 at 11:00 a.m. at Potomac, Maryland; the Board recommends voting FOR each proposal

22-10-2026

J.W. Mays, Inc. (MAYS) filed its DEF 14A proxy for its 2026 annual meeting (record date November 24, 2026), seeking shareholder votes on auditor ratification, an advisory say-on-pay resolution, and a non-binding frequency vote on future say-on-pay votes. Audit fees rose to $207,975 from $190,000 (total fees up to $266,975 from $263,578), while total rent expense under related-party leases with Weinstein Enterprises fell to $1,427,380 from $1,574,285. The company also agreed to a 30-month rent deferral with the affiliated landlord effective October 1, 2026, deferring $34,716 and $5,466 per month.

• · Lease on Jamaica Avenue at 169th Street extended to May 31, 2040; the remaining two five-year options to extend to 2050 are not reasonably certain to be exercised
• · Weinstein Enterprises purchased 508 Fulton Street in December 2024 from a landlord holding 25% of the property; rent payments to it began January 2025
• · Board makes no recommendation on the say-on-frequency proposal; absent a choice, proxies default to one year
• · Company discontinued its retail department store segment in 1989 and operates as a real estate business
• · Shareholder proposal deadline for the 2027 meeting is June 28, 2027; director nomination notice deadline is September 27, 2027

22-10-2026

DUKE Robotics Corp. (DUKR) filed a definitive DEF 14A proxy statement on October 22, 2026, calling its annual shareholder meeting for December 15, 2026 in Tel Aviv, Israel. Shareholders will vote on electing four directors, ratifying Somekh Chaikin (a KPMG member firm) as auditor for fiscal 2026, increasing the 2021 Equity Incentive Plan share reserve by 220,000 shares (from 480,000 to 700,000), and two nonbinding advisory votes on executive compensation and its frequency. The record date is October 22, 2026, with 3,425,978 common shares outstanding.

• · Annual meeting date and time: December 15, 2026 at 15:00 local time, Tel Aviv, Israel
• · Record date: October 22, 2026; only holders of record on that date may vote
• · Proposal 2 ratifies Somekh Chaikin (member firm of KPMG International) as auditor for fiscal year ending December 31, 2026
• · Proposal 3 seeks a 220,000-share increase to the 2021 Equity Incentive Plan reserve, a 45.8% increase over the current 480,000-share authorization
• · Proposal 5 asks shareholders for a nonbinding recommendation on whether say-on-pay votes occur every one, two, or three years
• · Abstentions count toward quorum but not toward proposal approval; blank proxies count for quorum but do not affect outcomes where no voting authority is conferred
• · Shareholders attending in person must bring an admission ticket or proof of share ownership
• · Filing identifies the company as a non-U.S. filer (Israel address) and a Nevada corporation, formerly UAS Drone Corp.

22-10-2026

InnovAge Holding Corp. (INNV) filed its DEF 14A proxy statement ahead of its December 3, 2026 virtual Annual Meeting of Stockholders. The filing seeks shareholder votes on election of Class III directors (John Ellis Bush, Patricia Fontneau, Ted Kennedy, Jr., Pavithra Mahesh), an advisory vote on say-on-pay frequency (Board recommends 1 year), an advisory say-on-pay vote, and ratification of Deloitte & Touche LLP as auditor for fiscal year ending June 30, 2027. The excerpt contains no reported financial results or dollar figures, so its investor-relevant content is governance-focused.

• · Voting deadline is 11:59 P.M. EST on December 2, 2026, with the virtual Annual Meeting held December 3, 2026 at 9:00 a.m. EST
• · Board recommends a 1-year frequency for future say-on-pay votes (Proposal 2)
• · Ratification of Deloitte & Touche LLP requires a majority of voting power present or represented and entitled to vote; the Audit Committee may reconsider or replace the auditor even if ratified
• · Audit Committee report states it reviewed FY2026 audited financial statements (Form 10-K for year ended June 30, 2026) and recommended their inclusion in the filing
• · Company is paying all solicitation costs, including reimbursement of brokerage and custodian forwarding expenses

22-10-2026

Copart, Inc. has filed its DEF 14A proxy statement for the 2026 annual meeting of stockholders, to be held Tuesday, December 1, 2026 at 8:00 a.m. CST at its Dallas, Texas headquarters, with a record date of October 9, 2026. Stockholders will vote on five items: election of directors, an advisory say-on-pay vote, ratification of Ernst & Young LLP as independent auditor, approval of an amendment, restatement and extension of the 2007 Equity Incentive Plan, and approval of a CEO Performance Award. The filing accompanies the Form 10-K for the fiscal year ended July 31, 2026, and the board recommends FOR on all five proposals.

• · Proxy materials are available on or about October 22, 2026 at www.edocumentview.com/CPRT
• · Voting is available via the Internet at www.investorvote.com/CPRT, by phone at 1-800-652-VOTE, or by mail
• · Fiscal 2026 covers the period ended July 31, 2026, and the filing includes a pay-versus-performance disclosure and a pay ratio section
• · Proposal 5 (CEO Performance Award) is detailed in Annex B and Proposal 4 (equity plan amendment) in Annex A

22-10-2026

Madison Square Garden Entertainment Corp. (MSGE) filed its DEF 14A proxy statement on October 22, 2026 for an annual meeting on December 10, 2026. The Board has nominated 12 directors (3 Class A, 9 Class B) for one-year terms, and seeks shareholder votes on director elections, ratification of the independent auditor, and an advisory vote on named executive officer compensation, with the Board recommending FOR on all three proposals. The filing references the 2026 Form 10-K for fiscal year ended June 30, 2026 but does not itself disclose period-over-period financial results.

• · Long-term incentive program mixes performance stock units (50%, cliff-vesting after three years based on Total Company Net Revenue and Business Unit AOI targets) and restricted stock units (50%, vesting ratably over three years).
• · Annual incentive cash pool is initially funded solely on AOI, which can be modified up or down based on business unit strategic, operational and financial objectives.
• · Restricted stock units for directors are subject to a holding requirement through end of Board service.
• · Board self-assessments are conducted at least annually, and Audit and Compensation Committees are composed entirely of independent directors.
• · The Company was initially incorporated in Delaware on September 15, 2022 and redomiciled as a Nevada corporation (per current description); Sphere Entertainment no longer owns any Company common stock as of September 22, 2023.

22-10-2026

Axil Brands, Inc. (AXIL) has filed its DEF 14A proxy statement for the annual meeting of stockholders, with proxy materials and the Notice of Internet Availability expected to be mailed on or about October 28, 2026, ahead of the 2026 Annual Report for the fiscal year ended May 31, 2026. Stockholders of record as of October 21, 2026 (6,822,681 common shares outstanding) will vote on two matters: the election of Nancy Hundt as a Class I director for a term expiring at the 2029 annual meeting, and ratification of Salberg & Company, P.A. as independent registered public accounting firm for fiscal year ending May 31, 2027. The filing is procedural and governance-focused, and contains no financial results or performance data in the excerpt provided.

• · Proposal 1 is the election of Nancy Hundt as a Class I director with a three-year term expiring at the 2029 Annual Meeting; stockholders may vote For or Withhold.
• · Proposal 2 seeks ratification of Salberg & Company, P.A. as auditor for fiscal year ending May 31, 2027; abstentions are permitted.
• · Uninstructed proxies will be voted For both the director nominee and the auditor ratification; no cumulative voting applies.
• · The filing includes pay-versus-performance and summary compensation table data for PEO and non-PEO NEOs across fiscal years 2023 to 2026, though the actual dollar figures are not present in the excerpt provided.

22-10-2026

Evolution Petroleum Corporation has filed its definitive DEF 14A proxy statement for its 2026 annual meeting of stockholders, to be held December 3, 2026 in Houston, Texas. Stockholders of record as of October 16, 2026 will vote on electing six directors, ratifying Baker Tilly US, LLP as independent auditor for fiscal year ending June 30, 2027, and an advisory vote on named executive officer compensation. The filing is a governance document with no reported financial results, so no performance comparison is presented.

• · Annual meeting date: Thursday, December 3, 2026 at 10:00 a.m. Central Time at 1155 Dairy Ashford Road, Suite 425, Houston, Texas
• · Record date for voting eligibility: October 16, 2026
• · Proxy materials first sent to stockholders on or about October 23, 2026
• · Fiscal year ended June 30, 2026 annual report (Form 10-K) made available with proxy materials
• · Company is a Nevada corporation
• · Broker non-votes: shares held in street name will not be voted on director elections or the say-on-pay advisory vote without voting instructions

22-10-2026

Reading International, Inc. (RDIB) has filed its definitive proxy statement (DEF 14A) for a virtual 2026 Annual Meeting of Class B stockholders on December 3, 2026, at 2:00 p.m. Eastern Time. Stockholders will vote on electing five directors, ratifying Grant Thornton, LLP as independent auditor for fiscal 2026, an advisory vote on executive compensation, and approving a 2,000,000-share increase to the Class A stock reserve under the 2020 Stock Incentive Plan. The filing is a routine governance document with no reported financial results, and the registration deadline for non-pre-registered holders is November 30, 2026.

• · Registration deadline for non-pre-registered Class B holders is 5:00 p.m. Eastern Time on Monday, November 30, 2026
• · Annual Meeting will be held exclusively by webcast at meetnow.global/MJ9U5WZ
• · Filing discloses a controlled company status and related-party transactions with Sutton Hill Capital and a live theater play investment
• · Proxy materials first distributed on or about October 22, 2026

22-10-2026

Processa Pharmaceuticals (PCSA) has filed a definitive proxy for a virtual Special Meeting on November 30, 2026, seeking stockholder approval of a reverse stock split (1-for-3 to 1-for-9, at the Board's discretion) and an adjournment proposal. The filing follows the July 28, 2026 completion of its merger with Vidya Therapeutics, Inc., alongside a roughly $200 million PIPE placement of Series A Preferred Stock, which will dilute legacy holders to about 1.4% of common stock, versus about 46% for former Vidya equityholders and about 52.6% for PIPE investors. The reverse split is a prerequisite for satisfying Nasdaq initial listing criteria triggered by the expected change of control.

• · Special Meeting set for Monday, November 30, 2026 at 10:00 a.m. ET, virtual only; record date October 21, 2026
• · Post-transaction, the Company expects to rename itself Vidya Therapeutics, Inc. and trade under ticker VDYA on Nasdaq Capital Market, contingent on approvals
• · Series A Preferred Stock auto-converts 1,000:1 into common upon approval of Required Company Stockholder Matters at the Conversion Special Meeting, subject to beneficial ownership limitations
• · Reverse split must be effective no later than one year from the Special Meeting date, without reduction in authorized shares
• · Support Agreements covering about 3.6% of outstanding common stock commit those holders to vote FOR the Reverse Stock Split Proposal
• · Board unanimously recommends voting FOR both Proposal No. 1 (reverse split) and Proposal No. 2 (adjournment)

22-10-2026

Aytu BioPharma's DEF 14A proxy seeks stockholder approval of a proposed amendment to the 2023 Equity Incentive Plan (Proposal No. 2), with the proposal set out in Appendix A. The plan reserve currently includes 500,000 shares plus 87,155 rolled-over shares, with 2,057 returning shares eligible for grant as of September 30, 2026, and the company has roughly 66 employees and four non-employee directors eligible to participate. The filing contains no financial results, so no period-over-period performance comparison is available.

• · The plan has no evergreen provision, so reserved shares do not automatically increase.
• · Option and SAR repricing is prohibited without stockholder approval, and cash buyouts of underwater options are barred.
• · Shares withheld for taxes, surrendered for exercise price, or repurchased with option proceeds are not recycled back into the reserve.
• · Awards are subject to clawback under company policy, Sarbanes-Oxley Section 304, and Dodd-Frank Section 954.
• · Stock options may not exceed a ten-year term (five years for ISOs to 10%+ holders), and post-termination exercise windows are three months generally and twelve months for disability or death.
• · The plan prohibits promissory notes as payment for option exercise.
• · Plan administration rests with the Compensation Committee, composed entirely of non-employee independent directors.